ELV
Elevance Health Inc. NYSE Listed Oct 30, 2001$388.50
-0.71%
vs $391.27
Mkt Cap $86.2B
52w Low $274.66
76.0% of range
52w High $424.43
50d MA $374.61
200d MA $341.20
P/E (TTM)
15.5x
EV/EBITDA
11.2x
P/B
2.0x
Debt/Equity
0.8x
ROE
11.9%
P/FCF
27.1x
RSI (14)
47.70
ATR (14)
$11.25
Beta
0.50
50d MA
$374.61
200d MA
$341.20
Avg Volume
1.8M
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
220 Virginia Avenue · Indianapolis, IN 46204 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | AMC | 11.03 | 12.58 | +14.1% | 328.20 | +0.4% | +5.5% | -0.4% | +3.4% | +1.8% | +3.8% | — |
| Jan 28, 2026 | AMC | 3.10 | 3.33 | +7.4% | 341.85 | +0.0% | +1.5% | -0.4% | -1.1% | -0.9% | +0.6% | — |
| Oct 21, 2025 | AMC | 4.93 | 6.03 | +22.3% | 349.75 | -0.8% | -1.3% | +0.3% | -1.1% | +0.0% | -0.9% | — |
| Jul 17, 2025 | AMC | 8.91 | 8.84 | -0.8% | 302.45 | -4.0% | -8.4% | -0.2% | +1.9% | +5.3% | -5.5% | — |
| Apr 22, 2025 | AMC | 11.41 | 11.97 | +4.9% | 415.90 | -0.3% | +2.6% | +0.4% | -1.7% | -1.9% | -0.0% | — |
| Jan 23, 2025 | AMC | 3.80 | 3.84 | +1.1% | 401.36 | -1.0% | -0.1% | +2.6% | -1.4% | -1.3% | -0.2% | — |
| Oct 17, 2024 | AMC | 9.66 | 8.37 | -13.4% | 444.35 | -1.8% | -3.1% | -2.0% | -0.6% | -1.0% | +0.8% | — |
| Jul 17, 2024 | AMC | 10.01 | 10.12 | +1.1% | 520.93 | -2.6% | -3.1% | -0.9% | +0.8% | -0.3% | +1.9% | — |
| Apr 18, 2024 | AMC | 10.53 | 10.64 | +1.0% | 525.19 | +1.4% | +1.2% | +0.2% | +0.1% | +0.2% | +1.1% | — |
| Jan 24, 2024 | AMC | 5.55 | 5.62 | +1.3% | 473.67 | -0.4% | +1.4% | +0.7% | +0.6% | +1.2% | +0.2% | — |
| Oct 18, 2023 | AMC | 8.45 | 8.99 | +6.4% | 469.31 | -0.2% | -1.3% | -2.1% | -0.4% | +0.2% | -0.6% | — |
| Jul 19, 2023 | AMC | 8.80 | 9.04 | +2.7% | 463.21 | +1.3% | +2.7% | +0.0% | -1.0% | +1.0% | -1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 20 | Deutsche Bank | Upgrade | Hold → Buy | $498 | $402.27 | $403.00 | +0.2% | -1.5% | -1.6% | +1.2% | -1.7% | +0.9% |
| Apr 29 | BofA Securities | Upgrade | Neutral → Buy | $435 | $362.74 | $365.20 | +0.7% | +3.8% | -0.1% | -1.0% | -0.2% | -0.8% |
| Apr 28 | JP Morgan | Maintains | Overweight → Overweight | — | $356.34 | $359.17 | +0.8% | +1.8% | +3.8% | -0.1% | -1.0% | -0.2% |
| Apr 24 | Guggenheim | Maintains | Buy → Buy | — | $346.29 | $348.00 | +0.5% | -0.4% | +3.4% | +1.8% | +3.8% | -0.1% |
| Apr 24 | Barclays | Maintains | Overweight → Overweight | — | $346.29 | $348.00 | +0.5% | -0.4% | +3.4% | +1.8% | +3.8% | -0.1% |
| Apr 23 | Baird | Maintains | Neutral → Neutral | — | $328.20 | $329.36 | +0.4% | +5.5% | -0.4% | +3.4% | +1.8% | +3.8% |
| Apr 23 | Evercore ISI | Maintains | In Line → In Line | — | $328.20 | $329.36 | +0.4% | +5.5% | -0.4% | +3.4% | +1.8% | +3.8% |
| Apr 20 | Jefferies | Maintains | Buy → Buy | — | $323.05 | $321.43 | -0.5% | -1.1% | +2.7% | +0.0% | +5.5% | -0.4% |
| Apr 13 | Truist | Maintains | Buy → Buy | — | $311.53 | $309.51 | -0.6% | +1.5% | -0.9% | -0.7% | +1.5% | +2.3% |
| Mar 11 | Mizuho | Maintains | Outperform → Outperform | — | $282.68 | $280.19 | -0.9% | +2.5% | -0.7% | +1.3% | +0.2% | +1.3% |
| Feb 2 | Truist | Maintains | Buy → Buy | — | $345.74 | $342.29 | -1.0% | -1.1% | -0.9% | +0.6% | -2.5% | +2.0% |
| Feb 2 | JP Morgan | Maintains | Overweight → Overweight | — | $345.74 | $342.29 | -1.0% | -1.1% | -0.9% | +0.6% | -2.5% | +2.0% |
| Jan 30 | Barclays | Maintains | Overweight → Overweight | — | $346.98 | $347.90 | +0.3% | -0.4% | -1.1% | -0.9% | +0.6% | -2.5% |
| Jan 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $346.98 | $347.90 | +0.3% | -0.4% | -1.1% | -0.9% | +0.6% | -2.5% |
| Jan 29 | Guggenheim | Maintains | Buy → Buy | — | $341.85 | $342.00 | +0.0% | +1.5% | -0.4% | -1.1% | -0.9% | +0.6% |
| Jan 22 | Guggenheim | Maintains | Buy → Buy | — | $369.88 | $368.66 | -0.3% | +0.6% | -0.3% | +1.6% | -14.3% | +5.9% |
| Jan 8 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $366.69 | $372.16 | +1.5% | +2.2% | -0.5% | +0.6% | -1.1% | +0.6% |
| Jan 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $371.37 | $373.13 | +0.5% | -1.3% | +2.2% | -0.5% | +0.6% | -1.1% |
| Jan 5 | Barclays | Maintains | Overweight → Overweight | — | $354.25 | $353.09 | -0.3% | +2.6% | +2.2% | -1.3% | +2.2% | -0.5% |
| Dec 19 | Deutsche Bank | Downgrade | Buy → Hold | — | $344.60 | $337.65 | -2.0% | -1.1% | +1.1% | -0.3% | +0.0% | +1.9% |
| Dec 18 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $345.96 | $342.08 | -1.1% | -0.4% | -1.1% | +1.1% | -0.3% | +0.0% |
| Nov 26 | TD Cowen | Maintains | Buy → Buy | — | $336.27 | $336.16 | -0.0% | +0.7% | -0.1% | -2.5% | +0.4% | -0.1% |
| Nov 4 | Mizuho | Maintains | Outperform → Outperform | — | $313.19 | $310.46 | -0.9% | +1.1% | +0.5% | -1.1% | +1.1% | -4.4% |
| Oct 28 | JP Morgan | Maintains | Overweight → Overweight | — | $342.49 | $342.49 | +0.0% | -0.9% | -0.9% | -4.3% | -1.5% | -1.3% |
| Oct 23 | TD Cowen | Maintains | Buy → Buy | — | $345.21 | $338.66 | -1.9% | +0.3% | -1.1% | +0.0% | -0.9% | -0.9% |
| Oct 22 | Barclays | Maintains | Overweight → Overweight | — | $349.75 | $346.98 | -0.8% | -1.3% | +0.3% | -1.1% | +0.0% | -0.9% |
| Oct 22 | Wells Fargo | Maintains | Overweight → Overweight | — | $349.75 | $346.98 | -0.8% | -1.3% | +0.3% | -1.1% | +0.0% | -0.9% |
| Oct 14 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $351.42 | $345.12 | -1.8% | -0.3% | -0.3% | -0.4% | +0.2% | +1.5% |
| Oct 10 | BofA Securities | Maintains | Neutral → Neutral | — | $358.13 | $360.23 | +0.6% | -1.4% | -0.5% | -0.3% | -0.3% | -0.4% |
| Oct 9 | Barclays | Maintains | Overweight → Overweight | — | $362.34 | $363.90 | +0.4% | -1.2% | -1.4% | -0.5% | -0.3% | -0.3% |
| Oct 9 | Mizuho | Maintains | Outperform → Outperform | — | $362.34 | $363.90 | +0.4% | -1.2% | -1.4% | -0.5% | -0.3% | -0.3% |
| Oct 8 | Guggenheim | Maintains | Buy → Buy | — | $357.49 | $358.11 | +0.2% | +1.4% | -1.2% | -1.4% | -0.5% | -0.3% |
| Oct 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $349.94 | $353.91 | +1.1% | +2.2% | +1.4% | -1.2% | -1.4% | -0.5% |
| Sep 5 | UBS | Maintains | Buy → Buy | — | $308.05 | $308.50 | +0.1% | +1.8% | -1.7% | +2.2% | -2.6% | +2.7% |
| Sep 4 | Barclays | Maintains | Overweight → Overweight | — | $321.59 | $308.60 | -4.0% | -4.2% | +1.8% | -1.7% | +2.2% | -2.6% |
| Aug 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $295.43 | $311.00 | +5.3% | +4.8% | -0.1% | +0.9% | -0.6% | -0.1% |
| Jul 25 | Baird | Maintains | Neutral → Neutral | — | $280.43 | $283.66 | +1.2% | +3.1% | -1.1% | +1.0% | +1.7% | -3.6% |
| Jul 22 | Barclays | Maintains | Overweight → Overweight | — | $276.45 | $275.99 | -0.2% | +1.9% | +5.3% | -5.5% | +3.1% | -1.1% |
| Jul 22 | JP Morgan | Maintains | Overweight → Overweight | — | $276.45 | $275.99 | -0.2% | +1.9% | +5.3% | -5.5% | +3.1% | -1.1% |
| Jul 21 | Argus | Downgrade | Buy → Hold | — | $277.09 | $278.35 | +0.5% | -0.2% | +1.9% | +5.3% | -5.5% | +3.1% |
| Jul 18 | Guggenheim | Maintains | Buy → Buy | — | $302.45 | $290.31 | -4.0% | -8.4% | -0.2% | +1.9% | +5.3% | -5.5% |
| Jul 18 | UBS | Maintains | Buy → Buy | — | $302.45 | $290.31 | -4.0% | -8.4% | -0.2% | +1.9% | +5.3% | -5.5% |
| Jul 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $302.45 | $290.31 | -4.0% | -8.4% | -0.2% | +1.9% | +5.3% | -5.5% |
| Jul 18 | Barclays | Maintains | Overweight → Overweight | — | $302.45 | $290.31 | -4.0% | -8.4% | -0.2% | +1.9% | +5.3% | -5.5% |
| Jul 18 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $302.45 | $290.31 | -4.0% | -8.4% | -0.2% | +1.9% | +5.3% | -5.5% |
| Jul 16 | Truist | Maintains | Buy → Buy | — | $336.21 | $337.60 | +0.4% | +2.5% | -12.2% | -8.4% | -0.2% | +1.9% |
| Jul 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $340.07 | $339.43 | -0.2% | -1.1% | +2.5% | -12.2% | -8.4% | -0.2% |
| Jul 14 | UBS | Maintains | Buy → Buy | — | $340.67 | $337.75 | -0.9% | -0.2% | -1.1% | +2.5% | -12.2% | -8.4% |
| Jul 9 | Barclays | Maintains | Overweight → Overweight | — | $349.46 | $347.00 | -0.7% | -0.9% | -0.1% | -1.5% | -0.2% | -1.1% |
| Jun 9 | Truist | Maintains | Buy → Buy | — | $393.36 | $392.65 | -0.2% | -1.0% | -1.5% | -0.8% | +1.4% | -0.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Penczek Ronald WOff | CAO & Controller | Sell | 369 | $403.16 | $149K | 3,740 | -1.02% | — |
| Jun 11, 2026 | Dixon Robert L JRDir | — | Sell | 151 | $401.77 | $61K | 10,734 | -0.54% | — |
| May 19, 2026 | Penczek Ronald WOff | CAO & Controller | Sell | 1,531 | $403.13 | $617K | 4,109 | -1.61% | +0.33% |
8-K · 7.01
! Medium
Elevance Health Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 10
8-K
Elevance Health Inc. -- 8-K Filing
I cannot provide a meaningful investment analysis based on this filing summary, as it contains only technical SEC metadata and schema references without substantive business information about Elevance Health.
May 13
8-K · 7.01
! Medium
Axogen, Inc. -- 8-K 7.01: Regulation FD Disclosure
Axogen disclosed a financial results presentation available for investor and analyst discussions, though the filing provides limited detail on specific business updates or financial performance metrics.
Apr 28
8-K
Elevance Health, Inc. -- 8-K Filing
Elevance Health issued forward-looking statements regarding financial projections, operational plans, and future performance, signaling management's expectations but acknowledging inherent uncertainties in predicting outcomes.
Apr 22
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An executive's equity compensation structure with performance conditions and service requirements suggests the company is retaining leadership talent while tying rewards to sustained performance, which could indicate confidence in strategic direction but also potential execution risks if targets aren't met.
Apr 2
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
CVS appointed Gallina, an independent director and audit committee financial expert, strengthening board oversight and governance credibility, which typically reassures investors about financial integrity and risk management.
Mar 19
8-K
Unknown — 8-K Filing
ELV's forward-looking guidance for 2026 earnings signals management confidence in sustained growth, making the stock attractive to investors seeking visibility into near-term profitability expansion.
Mar 10
8-K
Elevance Health, Inc. -- 8-K Filing
Elevance Health issued forward-looking statements regarding financial projections, operational plans, and future performance, which carry risks and may not materialize as anticipated.
Mar 2
8-K · 5.02
!!! Very High
Elevance Health, Inc. -- 8-K 5.02: Executive Change
Elevance Health's executive vice president of Carelon is departing May 2026 but staying as advisor through year-end to ensure operational continuity during leadership transition.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 14,345,459 | $4.2B | New | Mar 2026 |
| 2 | First Eagle Investment Management, Llc | 8,264,582 | $2.4B | Added | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 6,356,077 | $1.9B | New | Mar 2026 |
| 4 | Morgan Stanley | 5,042,246 | $1.8B | Reduced | Dec 2025 |
| 5 | Sanders Capital, Llc | 5,894,303 | $1.7B | Added | Mar 2026 |
| 6 | Artisan Partners Limited Partnership | 5,127,175 | $1.5B | Added | Mar 2026 |
| 7 | Invesco Ltd. | 4,817,410 | $1.4B | Added | Mar 2026 |
| 8 | Bank Of New York Mellon Corp | 2,845,280 | $833M | Added | Mar 2026 |
| 9 | Bank Of America Corp /de/ | 2,718,766 | $796M | Added | Mar 2026 |
| 10 | Amundi | 2,693,664 | $789M | New | Mar 2026 |
| 11 | Northern Trust Corp | 2,158,025 | $632M | Reduced | Mar 2026 |
| 12 | Fmr Llc | 1,975,719 | $578M | Added | Mar 2026 |
| 13 | Nuveen, Llc | 1,960,705 | $574M | Reduced | Mar 2026 |
| 14 | Grantham, Mayo, Van Otterloo & Co. Llc | 1,938,276 | $564M | Reduced | Mar 2026 |
| 15 | Citadel Advisors Llc | 1,562,219 | $457M | Reduced | Mar 2026 |
| 16 | Ruane, Cunniff & Goldfarb L.p. | 1,387,968 | $406M | Reduced | Mar 2026 |
| 17 | Baupost Group Llc/ma | 1,275,154 | $373M | — | Mar 2026 |
| 18 | Arrowstreet Capital, Limited Partnership | 1,225,800 | $359M | Reduced | Mar 2026 |
| 19 | Jpmorgan Chase & Co | 1,069,955 | $305M | Added | Mar 2026 |
| 20 | Newport Trust Company, Llc | 985,188 | $288M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | VANGUARD WINDSOR II FUND | 3,066,206 | $1.1B | Jan 2026 |
| 2 | First Eagle Global Fund | 2,844,869 | $984M | Jan 2026 |
| 3 | Fidelity 500 Index Fund | 2,828,270 | $905M | Feb 2026 |
| 4 | iShares Core S&P 500 ETF | 2,838,919 | $831M | Mar 2026 |
| 5 | VANGUARD HEALTH CARE FUND | 1,879,405 | $650M | Jan 2026 |
| 6 | VANGUARD DIVIDEND GROWTH FUND | 1,671,797 | $578M | Jan 2026 |
| 7 | MFS Value Fund | 1,513,108 | $484M | Feb 2026 |
| 8 | VANGUARD DIVIDEND APPRECIATION INDEX FUND | 1,207,776 | $418M | Jan 2026 |
| 9 | VANGUARD HIGH DIVIDEND YIELD INDEX FUND | 886,945 | $307M | Jan 2026 |
| 10 | BlackRock Equity Dividend Fund | 729,161 | $252M | Jan 2026 |
| 11 | GMO Quality Fund | 759,284 | $243M | Feb 2026 |
| 12 | Washington Mutual Investors Fund | 686,979 | $238M | Jan 2026 |
| 13 | Invesco Comstock Fund | 614,311 | $212M | Jan 2026 |
| 14 | Schwab S&P 500 Index Fund | 499,874 | $173M | Jan 2026 |
| 15 | First Trust Rising Dividend Achievers ETF | 554,630 | $162M | Mar 2026 |
| 16 | Invesco S&P 500 Equal Weight ETF | 467,218 | $162M | Jan 2026 |
| 17 | Sequoia Fund Inc | 532,467 | $156M | Mar 2026 |
| 18 | BNY Mellon Dynamic Value Fund | 475,636 | $152M | Feb 2026 |
| 19 | iShares MSCI USA Min Vol Factor ETF | 432,565 | $150M | Jan 2026 |
| 20 | State Street(R) SPDR(R) Portfolio S&P 500(R) ETF | 463,653 | $136M | Mar 2026 |
Valuation
Market Cap
$86.17B
Enterprise Value
$108.00B
P/E (TTM)
15.47x
Forward P/E
14.51x
PEG Ratio
-5.63x
P/B
1.96x
P/S
0.43x
P/FCF
27.15x
EV/EBITDA
11.18x
Shares Out
221.8M
Financials (TTM)
Revenue
$199.12B
Net Income
$5.66B
EBITDA
$9.66B
Free Cash Flow
$3.17B
Op Cash Flow
$4.29B
EPS Basic
$25.18
EPS Diluted
$25.12
EPS Forward
$26.77
Gross Margin
25.6%
Op Margin
4.1%
Net Margin
2.8%
Balance Sheet
Total Assets
$121.49B
Total Liab.
$77.47B
Total Equity
$44.03B
Cash
$9.49B
LT Debt
$31.33B
Book Value/Sh
$198.49
Debt/Equity
0.76x
Current Ratio
1.24
Quick Ratio
1.24
Returns & Growth
ROE
11.9%
ROA
4.2%
ROIC
6.7%
Rev Growth YoY
+12.6%
EPS Growth YoY
-2.4%
Price Returns
2W
-0.9%
1M
+4.5%
3M
+22.9%
6M
+16.2%
12M
+2.4%
Technicals
52W High
$424.43
52W Low
$274.66
50d MA
$374.61
200d MA
$341.20
RSI (14)
47.70
ATR (14)
$11.25
Beta
0.50
Avg Volume
1.8M
Dividends
Div Rate
$6.89
Div Yield
1.8%
Frequency
4
Ex-Div Date
Jun 10, 2026
Analyst Price Targets
Consensus
$382.38
High
$425.00
Low
$331.00
Median
$391.00
Data updated apr 25, 2026 6:59am
· Source: financialmodelingprep.com